CONTENTS
Plenary Session I
[8] Phase III Trial of Rituximab-CHOP (R-CHOP) vs. CHOP with a Second Randomization to Maintenance Rituximab (MR) or Observation in Patients 60 Years of Age and Older with Diffuse Large B-Cell Lymphoma (DLBCL). Session Type: Plenary Session
Signaling Pathway Deregulation
[76] Targeted Inhibition of NPM-ALK Gene Expression with Resultant Decreased Cell Viability by Tumor-Specific Small Interfering RNAs in Anaplastic Large Cell Lymphoma. Session Type: Oral Session
Chemotherapy/Rituximab Combinations and Radioimmunotherapy
[87] An International Multi-Centre, Randomized, Open-Label, Phase III Trial Comparing Rituximab Added to CVP Chemotherapy to CVP Chemotherapy Alone in Untreated Stage III/IV Follicular Non-Hodgkins Lymphoma. Session Type: Oral Session
[88] Introduction of Combined CHOP-Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma (DLBC) in British Columbia (BC). Session Type: Oral Session
89] The BEXXAR Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab) Produced Durable Complete Remissions in Heavily Pretreated Patients with Non-Hodgkins Lymphoma (NHL), Rituximab-Relapsed/Refractory Disease, and Rituximab-Naive Disease. Session Type: Oral Session
[90] CHOP Followed by Tositumomab/Iodine I 131 Tositumomab (BEXXAR) for Treatment of Newly Diagnosed Follicular Non-Hodgkins Lymphomas: A Phase II Trial of the Southwest Oncology Group (S9911). Session Type: Oral Session
[91] Assessment of Treatment-Related Myelodysplastic Syndromes (tMDS) and Acute Myeloid Leukemia (tAML) in Patients with Low-Grade Non-Hodgkins Lymphoma (LG-NHL) Treated with Tositumomab and Iodine-131 Tositumomab (the BEXXAR Therapeutic Regimen). Session Type: Oral Session
[92] Phase I Clinical Trial of Zevalin (90Y-Ibritumomab) in Patients with B-Cell Non-Hodgkins Lymphoma (NHL) with Relapsed Disease Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT). Session Type: Oral Session
Experimental Transplantation: Engraftment
[121] Priming/Increasing Responsiveness of Hematopoietic Stem/Progenitor Cells (HSPC) to an SDF-1 Gradient as a New Strategy to Improve Their Engraftment after Transplantation. Session Type: Oral Session
Cell Processing: Mobilization I
[123] Optimizing the Use of AMD 3100, a CXCR-4 Antagonist, for Mobilization of Hematopoietic Progenitor Cells: Studies in Healthy Volunteers. Session Type: Oral Session
Immunotherapy
[126] G-CSF Stimulation Results in a Higher Concentration of CD123+ Dendritic Cells and Immature B Cells in Bone Marrow Harvests Compared to Peripheral Blood: A Potential Explanation for Differences in Graft-Versus-Host Disease after Transplantation of These Two Sources of Cells. Session Type: Oral Session
Disordered Gene Expression in Hematologic Malignancy II
[2128] T-Cell Acute Lymphoblastic Leukemia and T-Cell Lymphoblastic Lymphoma: One Disease or Two? Session Type: Poster Session 299-II
Clinicopathologic/Molecular Factors Impacting Prognosis II
[2317] Relapse in Follicular Lymphoma Is Associated with the Acquisition of BCL6 Rearrangements, p53 and p16 Deletions: A Matched Pair Analysis. Session Type: Poster Session 488-II
[2318] Prevalence and Frequency of BCL-2/JH Translocations in Healthy Individuals: Implications for Diagnosis and Monitoring Patients with Follicular Lymphoma. Session Type: Poster Session 489-II
[2320] Subcutaneous Panniculitis-Like T Cell Lymphoma: Clinical Presentation and Follow up of 17 Patients. Session Type: Poster Session 491-II
[2321] Integrated PET Plus CT-Based Response Assessment of Aggressive Non-Hodgkins Lymphoma. Session Type: Poster Session 492-II
[2322] Diffuse Large B-Cell Lymphoma (DLBCL): Clinico-Pathologic Features and Outcome According to the Nodal or Extranodal Primary Origin. Session Type: Poster Session 493-II
[2323] Comparison of Conventional Staging Studies and FDG-PET Imaging in Hodgkins, Diffuse Large B-Cell and Follicular Lymphomas. Session Type: Poster Session 494-II
[2325] Clinical, Morphologic and Genetic Characterization of Grade 3 Follicular Lymphomas. Session Type: Poster Session 496-II
[2326] Both CD4-Positive and CD4-Negative Subtypes of Blastic Natural Killer Cell Lymphoma Constitute Distinct Disease Entities. Session Type: Poster Session 497-II
[2329] Diffuse Large B Cell Lymphoma: Characterisation of Immunohistochemical and Interim PET Scan Analysis and Correlation with Outcome. Session Type: Poster Session 500-II
[2333] Lymphocyte Recovery as a Positive Predictor of Prolonged Survival after Autologous Peripheral Blood Stem Cell Transplantation in T-Cell Non-Hodgkin Lymphoma. Session Type: Poster Session 504-II
[2334] Elevated Serum Soluble CD44 (sCD44) Level Is Associated with Unfavorable Features, Shorter Relapse-Free Survival, and Worse Overall Survival in Patients with Indolent Non-Hodgkins Lymphomas (NHL). Session Type: Poster Session 505-II
[2343] Value of FDG-PET in the Initial Staging of Non-Hodgkins Lymphomas: Comparison with Computed Tomography and Prognostic Implications. Session Type: Poster Session 514-II
Lymphoma: Treatment and Supportive Care
[2346] Promising Activity of the Proteasome Inhibitor Bortezomib (Velcade) in the Treatment of Indolent Non-Hodgkins Lymphoma and Mantle Cell Lymphoma. Session Type: Poster Session 517-II
[2348] Single Dose Per Cycle Pegfilgrastim Successfully Supports Full Dose Intensity CHOP-14 in Patients over 60 Years with Non-Hodgkins Lymphoma (NHL) and Successfully Mobilises Peripheral Blood Progenitor Cells (PBPC). Session Type: Poster Session 519-II
[2349] Phase I/II Study of Bortezomib Combined with Dose Adjusted-EPOCH Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. Session Type: Poster Session 520-II
[2350] IL-2 Does Not Protect Against Fludarabine and Cyclophosphamide Induced Immunosuppression. Session Type: Poster Session 521-II
[2353] Multiply Relapsed Diffuse, Aggressive Non-Hodgkins Lymphoma (NHL) Patients Respond to Single Agent Sphingosomal Vincristine. Session Type: Poster Session 524-II
[2356] Delayed Response to Fludarabine in Lymphoplasmacytic Lymphoma/Waldenstroms Macroglobulinemia. Session Type: Poster Session 527-II
[2358] Angiotensin II Recepter Blocker Prevents Acute Cardiotoxicity Following CHOP. Session Type: Poster Session 529-II
[2359] Phase II Study of Compound GW506U78 (AraG) for Patients with Indolent B-Cell or Peripheral T-Cell Lymphoma Previously Treated with Chemotherapy. Session Type: Poster Session 530-II
[2360] Results of a Phase II Study of Pentostatin in Advanced T-Cell Lymphoid Malignancies. Session Type: Poster Session 531-II
[2361] Phase II Study of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma (NHL). Session Type: Poster Session 532-II
[2363] SDX-105 (Bendamustine), a Clinically Active Antineoplastic Agent Posesses a Unique Mechanism of Action. Session Type: Poster Session 534-II
[2364] Results of a Phase I/II Trial with BBR-2778 (Pixantrone), Methylprednisolone, Cisplatin, and Cytosine Arabinoside (BSHAP) in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma (NHL). Session Type: Poster Session 535-II
[2365] A Single Pegfilgrastim Dose Per Cycle Supports Dose-Dense (q14d) CHOP-R in Patients with Non-Hodgkins Lymphoma. Session Type: Poster Session 536-II
[2368] Low-Dose Weekly Paclitaxel for Relapsed or Refractory Aggressive Non-Hodgkins Lymphoma. Session Type: Poster Session 539-II
[2369] A Phase I Study of Pixantrone (BBR 2778) in Combination with Cyclophosphamide, Vincristine and Prednisone in Patients with Relapsed Aggressive Non-Hodgkins Lymphoma. Session Type: Poster Session 540-II
[2370] HIV-Infected Patients with Diffuse Large B-Cell Lymphoma Treated with CHOP and HAART Have Similar Outcome Than HIV-Negative Patients Receiving CHOP. Session Type: Poster Session 541-II
[2371] Front-Line Chemotherapy Treatment with Gemcitabine in 20 Cutaneous T-Cell Lymphoma Patients. Session Type: Poster Session 542-II
[2372] Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue of the Orbit and Orbital Adnexa. Session Type: Poster Session 543-II
[2373] Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Previously Treated and Untreated Non-Hodgkins Lymphoma (NHL). Session Type: Poster Session 544-II
Lymphoma: New Agents
[2374] A Phase II Trial of the Rapamycin Analog CCI-779 in Previously Treated Mantle Cell Non-Hodgkins Lymphoma: Interim Analysis of 18 Patients. Session Type: Poster Session 545-II
[2375] Retreatment of NHL with Epratuzumab (Humanized Anti-CD22) Can Result in Second Responses and Is Well Tolerated. Session Type: Poster Session 546-II
[2376] A Pilot Study of Epratuzumab and Rituximab in Combination with CHOP Chemotherapy (ER-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Session Type: Poster Session 547-II
[2377] Pharmacokinetics of Rituximab and Epratuzumab during Concomitant Administration of the Two Antibodies in Patients with B-Cell NHL. Session Type: Poster Session 548-II
[2378] Very High Response Rates in Previously Untreated T- Cell Prolymphocytic Leukaemia Patients Receiving Alemtuzumab (Campath-1H) Therapy. Session Type: Poster Session 549-II
[2379] Acquirement of Resistance to Rituximab Is Associated with Upregulation of CD52 Antigen: The Role of Targeting CD52 Antigen Using Alemtuzumab (CAMPATH 1-H) in Rituximab-Resistant Non-Hodgkins Lymphoma (NHL) Cell Lines. Session Type: Poster Session 550-II
[2380] Activity of Alemtuzumab (Mabcampath) in Relapsed / Refractory Waldenstrms Macroglobulinemia. Session Type: Poster Session 551-II
[2381] Promising Therapeutic Activity of a New Drug Immunoconjugate, IMMU-110, in a Human Burkitt Lymphoma Model. Session Type: Poster Session 552-II
[2383] HuMax-CD4, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Phase II Trial in Cutaneous T Cell Lymphoma (CTCL). Session Type: Poster Session 554-II
[2384] A Pilot Study of Alemtuzumab (Anti-CD 52 Monoclonal Antibody) Therapy for Patients with Relapsed or Chemotherapy-Refractory Peripheral T-Cell Lymphomas. Session Type: Poster Session 555-II
[2385] Preclinical Antitumor Activity of a Humanized Anti-CD40 Monoclonal Antibody SGN-40. Session Type: Poster Session 556-II
[2386] Comparative Efficacy of Rituximab and a Fully Human Anti-CD40 Antagonist Antibody in In Vitro and in Xenograft Lymphoma Models. Session Type: Poster Session 557-II
[2390] Safety, Antitumor Activity and Pharmacokinetics of Six Weekly Doses of SGN-30 (anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies. Session Type: Poster Session 561-II
[2391] A Pilot Study of MDX-010 after Vaccine Failure in Patients with Advanced Malignancy. Session Type: Poster Session 562-II
[2393] Results of a Phase I/II Multicenter Trial of Galiximab (IDEC-114, Anti-CD80 Antibody) Therapy for Relapsed or Refractory Follicular Lymphoma. Session Type: Poster Session 564-II
[2395] Heat Shock Protein 90 (hsp90) Inhibitors: A Novel Class of Agents with Activity Against Waldenstroms Macroglobulinemia (WM): Pre-Clinical Studies, and Molecular Profiling and Clinical Implications. Session Type: Poster Session 566-II
[2399] Desferroxamine and Curcumin, Two Agents with Anti-Cyclin D1/D3 Activity in Mantle Cell Lymphoma and Multiple Myeloma Cell Lines. Session Type: Poster Session 570-II
[625] Phase II Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) for Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL). Session Type: Oral Session
[626] Treatment of Angioimmunoblastic T-Cell Lymphoma (AILD) with Cyclosporine. Session Type: Oral Session
[627] Report of a Phase II Study of Proteasome Inhibitor Bortezomib (VELCADE) in Patients with Relapsed or Refractory Indolent or Aggressive Lymphomas. Session Type: Oral Session
[628] Oblimersen (Bcl-2 Antisense) Enhances the Antitumor Activity of Bortezomib (Bor) in Multiple Myeloma (MM) and Non-Hodgkins Lymphoma (NHL) Preclinical Models. Session Type: Oral Session
[630] Preclinical Evaluation of a Humanized Anti-CD74 Monoclonal Antibody, hLL1, for Treatment of B-Cell Malignancies. Session Type: Oral Session
[631] The Proteasome Inhibitor Bortezomib (PS-341) Is Active Against Waldenstroms Macroglobulinemia (WM). Session Type: Oral Session
[632] Phase I/II Study of a Fully Human Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkins Disease (HD) and Anaplastic Large Cell Lymphoma (ALCL). Session Type: Oral Session
Transplantation Regimen Toxicities and Engraftment II
[2602] Comparable Progression Free Survival and Overall Survival for Patients >50 Years of Age Receiving Allogeneic Nonmyeloablative and Myeloablative Transplantation. Session Type: Poster Session 773-II
[2610] Low Transplant Related Mortality with Allogeneic Stem Cell Transplantation in Elderly (Above 60 Years) Patients. Session Type: Poster Session 781-II
[2611] Alemtuzumab (Campath)-Based GVHD Prophylaxis Leads to Improved Survival after Allogeneic Transplantation for Patients with Advanced Hematologic Malignancies. Session Type: Poster Session 782-II
[2612] Allogeneic Myeloablative Transplantation for Elderly Patients Aged 50 or Older. Session Type: Poster Session 783-II
[2615] Non Myeloablative Allogeneic Related Transplant in Patients with Bad Prognosis Non-Hodgkins Lymphoma: A Multicenter Cooperative Study. Session Type: Poster Session 786-II
[2617] Correlation between Busulphan Concentration and Transplantation Related Toxicity in Patients Undergoing SCT. Session Type: Poster Session 788-II
[2623] Donor T Lymphocyte Engraftment Is Facilitated by Higher CD34 Cell Doses in T Cell Depleted Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT). Session Type: Poster Session 794-II
[2629] Intravenous vs. Oral Busulfan-Based Conditioning Therapy Prior to Allogeneic Bone Marrow Transplantation - A Case Controlled Study. Session Type: Poster Session 800-II
GVHD
[2646] Phase II Study of Denileukin Diftitox (Ontak) for Treatment of Steroid Resistant Acute Graft Versus Host Disease . Session Type: Poster Session 817-II
[2656] Impact of Age on Transplant Related Mortality (TRM) Following Fludarabine and Cyclophosphamide-Based Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). Session Type: Poster Session 827-II
[2658] Low-Dose (50 mg) Alemtuzumab (Campath) in Myeloablative Allogeneic Stem Cell Transplantation for CD52+ Aggressive Hematological Malignancies: Decreased Incidence of Acute Graft-Versus-Host Disease (aGVHD), with Unique Pharmacokinetics. Session Type: Poster Session 829-II
[2661] Photopheresis in Management of Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem-Cell Transplant. Results from a Retrospective Analysis. Session Type: Poster Session 832-II
Chronic GVHD: Quality of Life and Recurrent Malignancy After Transplantation
[2664] Pravastatin for the Treatment of Refractory Chronic GVHD. Prospective Clinical and Immunological Evaluation from the Japan Hematology Oncology Clinical Study Group (J-HOCS). Session Type: Poster Session 835-II
[2665] Anti-CD20 Monoclonal Antibody Treatment in Six Patients with Chronic Graft-Versus-Host Disease. Session Type: Poster Session 836-II
[2668] Depression and Anxiety before Hematopoietic Stem Cell Transplantation Are Associated with Increased Mortality. Session Type: Poster Session 839-II
[2671] Fatigue in Long-Term Survivors of Allogeneic Stem Cell Transplantation: Prevalence, Severity and Associated Risk Factors. Session Type: Poster Session 842-II
[2675] The Implication of Follicular Lymphoma (FL) Patients Receiving Allogeneic Stem Cell Transplantation from Donors Carrying t(14;18) Positive Cells. Session Type: Poster Session 846-11
[2682] The Role of Radiation as Risk Factor for Late Non-Relapse Death after Allogeneic Stem Cell Transplantation. Session Type: Poster Session 853-II
[2685] Depicting Treatment Failure after Non-Myeloablative Allogeneic Transplantation (NMAT): The Concept of Sustained Relapse. Session Type: Poster Session 856-II
Non-Myeloablative Matched Related Donor Transplantation
[2691] Response To Salvage Chemotherapy Influences Outcome of Reduced-Intensity Allogeneic Stem Cell Transplantation for Non-Hodgkins Lymphoma but Does Not Preclude Durable Survival. Session Type: Poster Session 862-II
[2696] Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with a Reduced-Intensity Regimen (RIST) for Non-Hodgkin Lymphoma (NHL): A Retrospective Survey of 112 Adults Patients in Japan. Session Type: Poster Session 867-II
[2701] Single Institution Experience with a Non-Myeloablative Allogeneic Stem Cell Transplant Conditioning Regimen Using Fludarabine and Total Body Irradiation (TBI). Session Type: Poster Session 872-II
[2702] Complete Remission of Late Stage Mycosis Fungoides/Sezary Syndrome Following Allogeneic Transplantation. Session Type: Poster Session 873-II
[2704] Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Adult T-Cell Leukemia /Lymphoma (ATL)- Multicenter Phase I Clinical Trial. Session Type: Poster Session 875-II
[2707] Comparison of the Outcomes Following Conventional Hematopoietic Stem Cell Transplantation (HSCT) vs. Reduced-Intensity Stem Cell Transplantation (RIST) in Older Patients with Hematologic Malignancies. Session Type: Poster Session 878-II
Autologous Transplantation: Leukemia/Lymphoma
[2707.5] Late Mortality in Two-Year Survivors of Autologous Hematopoietic Cell Transplantation (HCT): Report from the BMT Survivor Study (BMTSS). Session Type: Poster Session 878.5-II
[2708] Does Follicularity in Large Cell Lymphoma Predict Outcome Following Autologous Stem Cell Transplantation (ASCT)? Session Type: Poster Session 879-II
[2709] Long Term Relapse Free Survival Is Possible after Autologous Transplantation for Follicular Lymphoma. Session Type: Poster Session 880-II
[2710] Autologous Stem Cell Transplantation in Induction Failure Patients with Peripheral T-Cell Lymphoma: The GEL/TAMO Experience. Session Type: Poster Session 881-II
[2711] Long-Term Follow-Up Indicates No Significant Survival Difference between High and Low Risk, High Grade NHL (hgNHL) Patients Having Undergone High Dose Chemotherapy (HDCT) with Autologous Stem Cell Transplantation (aSCT). Session Type: Poster Session 882-II
[2712] Meta-Analysis of Randomised Trials Comparing High-Dose Chemotherapy with Autologous Stem Cell Support as Part of First-Line Therapy with Conventional Chemotherapy in Aggressive Non-Hodgkin Lymphoma - First Results. Session Type: Poster Session 883-II
[2713] Early Autologous Transplantation for Mantle Cell Lymphoma May Improve Long Term Disease-Free Survival . Session Type: Poster Session 884-II
[2714] Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide Purging Produces Durable Remissions in Patients with Follicular Lymphoma. Session Type: Poster Session 885-II
[2715] Repeated High-Dose Therapy with Rituximab Followed by Autologous Stem Cell Transplantation (ASCT) as Primary Treatment of High-Risk Aggressive NHL. Session Type: Poster Session 886-II
[2716] Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stem Cell Transplantation (ASCT) for Relapsed Aggressive B-Cell Non-Hodgkins Lymphomas (NHL): The Impact of Histologies of Follicular (FL) Origin. Session Type: Poster Session 887-II
[2718] Predictive Factors of Survival Following Autologous Stem Cell Transplant (ABMT) for Follicular NHL. Session Type: Poster Session 889-II
[2720] Autotransplant in Patients Aged 60 Years and above with Relapsed / Refractory Non-Hodgkins Lymphoma: Inferior Survival in Patients Treated with TBI-Containing Regimen and Extensive Prior Therapy. Session Type: Poster Session 891-II
[2721] High-Dose Carmustine, Etoposide, Cisplatin, Autologous Stem Cell Transplant and Involved-Field Radiotherapy for Relapsed/Refractory Lymphoma: An Effective Regimen with Low Mortality. Session Type: Poster Session 892-II
[2726] Double Induction Combined with Tandem Autologous Stem Cell Transplantation in Relapsed and Refractory Aggressive Lymphomas. Session Type: Poster Session 897-II
Rituximab and Biologic Combinations
[231] Scheduled Rituximab Maintenance Therapy Versus Rituximab Retreatment at Progression in Patients with Indolent Non-Hodgkins Lymphoma (NHL) Responding to Single-Agent Rituximab: A Randomized Trial of the Minnie Pearl Cancer Research Network. Session Type: Oral Session
[232] Combination Immunotherapy for Non-Hodgkins Lymphoma (NHL) with a CpG Oligonucleotide (1018 ISS) and Rituximab: Biological Responses through Increased Interferon-a/-Inducible Gene Expression without Significant Toxicity. Session Type: Oral Session
[233] Multi-Center, Phase 2 Study of Combination Antibody Therapy with Epratuzumab Plus Rituximab in Recurring Low-Grade NHL. Session Type: Oral Session
[236] Short Intensive Chemotherapy with Rituximab Seems Successful in Burkitt NHL, Mature B-ALL and Other High-Grade B-NHL. Session Type: Oral Session
CLL: Therapy I
[245] The Addition of Rituximab to Fludarabine Significantly Improves Progression-Free and Overall Survival in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Session Type: Oral Session
Experimental Transplantation: Regimens
[255] Non-Myeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients with Non-Hodgkins Lymphoma (NHL)Whose Disease Has Failed a Prior Autologous Stem Cell Transplantation (ASCT). Session Type: Oral Session
Non Myeloablative Transplantation
[261] Morbidity and Mortality with Nonmyeloablative Compared to Myeloablative Conditioning before Hematopoietic Cell Transplantation from HLA Matched Related Donors. Session Type: Oral Session
[262] Transplant-Related Toxicities (TRT) and Mortality Following HLA-Matched Unrelated Donor Hematopoietic Cell Transplantation (URD-HCT) Using Nonmyeloablative (NM) Compared to Myeloablative (M) Conditioning: Influence of Pretransplant Comorbidities. Session Type: Oral Session
[265] Non-Myeloabalative Stem Cell Transplantation (NST) for Mantle Cell Lymphoma in the United Kingdom. A Report of the Clinical Trials Committee of the British Society for Blood and Marrow Transplantation. Session Type: Oral Session
Myeloablative Matched Related Donor Transplantation
[270] Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older. Session Type: Oral Session
Clinicopathologic and Molecular Factors Impacting Prognosis
[345] Rituximab (R) Alters the Prognostic Indicator Profile in Diffuse Aggressive Non-Hodgkin Lymphomas. Session Type: Oral Session
[349] Novel Fully Human CD20 Antibodies with Different Mechanisms of Action. Session Type: Oral Session
Non-Hodgkin Lymphoma: Treatment I
[351] Combined Immuno-Chemotherapy (R-FCM) Results in Superior Remission and Survival Rates in Recurrent Follicular and Mantle Cell Lymphoma Final Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). Session Type: Oral Session
[352] Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves Time To Treatment Failure in First Line Therapy of Follicular Lymphoma Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). Session Type: Oral Session
[353] Bendamustine and Rituximab Act Synergistically In Vitro and Are Effective in the Treatment of Relapsed or Refractory Indolent and Mantle-Cell Lymphomas. Session Type: Oral Session
[354] Comparison of CHVP + Interferon with CHOP Followed by Autologous Stem Cell Transplantation with a TBI Conditioning Regimen in Untreated Patients with High Tumor Burden Follicular Lymphoma: Results of the Randomized GELF94 Trial (G.E.L.A. Study Group). Session Type: Oral Session
[355] The Length of Treatment of Aggressive Non Hodgkins Lymphomas According to the International Prognostic Index Score. Some Lessons from the GISL LA03 Study. Session Type: Oral Session
[356] Dose-Adjusted EPOCH-Rituximab in Untreated Diffuse Large B-Cell Lymphoma: Benefit of Rituximab Appears Restricted to Tumors Harboring Anti-Apoptotic Mechanisms. Session Type: Oral Session
Vaccine and Dendritic Cell-Based Therapies
[357] Recombinant Idiotype-KLH Vaccination (MyVax) Following CHOP Chemotherapy in Mantle Cell Lymphoma. Session Type: Oral Session
[359] Dendritic Cell-Based Therapy for the Treatment of Mantle Cell Lymphoma. Session Type: Oral Session
[360] Treatment of Murine Lymphoma by the Combined Effect of Intratumoral Injection of Dendritic Cells and Systemic Chemotherapy. Session Type: Oral Session
[361] Dendritic Cells Co-Cultured with Antibody-Coated Tumor Cells Provide Protective Immunity Against B Cell Lymphoma In Vivo. Session Type: Oral Session
Secondary Malingancy and Late Complications After Transplantation
[393] Second Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation. Session Type: Oral Session
[396] Ten-Year Follow-Up of the First 100 Patients Having Received High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkins Disease in Vancouver: Long-Term Complications and Causes of Death. Session Type: Oral Session
[397] High-Dose Chemotherapy (HDCT) and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) Does Not Increase the Risk of Second Neoplasms for Patients with Hodgkins Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by AHSCT. Session Type: Oral Session
Immunodeficienty, Including HIV Infection
[421] Rituximab and Infusional Cyclophosphamide, Doxorubicin and Etoposide (CDE) in Combination with HAART: A Safe and Highly Active Regimen in HIV-Related Non-Hodgkins Lymphomas (NHL). Session Type: Oral Session
Non-Hodgkin Lymphoma: Treatment II - Adult and Pediatric
[489] Taxol Plus Topotecan Plus Rituximab (TTR) with G-CSF Support: An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL) Who Failed CHOP-Like and Platinum-Based Therapy. Session Type: Oral Session
[490] Genasense (Oblimersen Sodium, G3139) Is Active and Well-Tolerated Both Alone and with R-CHOP in Mantle Cell Lymphoma (MCL). Session Type: Oral Session
[494] Impact of Cranial Radiotherapy on CNS Prophylaxis in Children and Adolescents with CNS-Negative Lymphoblastic Lymphoma Stage III/IV Treated with an Intensive ALL-Type Chemotherapy. Session Type: Oral Session
Genomic and Proteomic Profiling
[617] A Molecular Predictor of Survival Following Diagnosis of Follicular Lymphoma. Session Type: Oral Session
Chronic GVHD and Recurrent Malignancy after Transplantation
[521] Low Dendritic Cell (DC) Count after Allogeneic Stem Cell Transplantation (SCT) Predicts Death, Relapse, and Acute Graft-versus-Host Disease (AGVHD). Session Type: Oral Session
[524] Risk Factors for Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation for Treatment of Hematological Malignancies. Session Type: Oral Session
Transplant regimen toxicities and engraftment
[676] Treatment of Mucositis with Palifermin Improves Patient Function and Results in a Clinically Meaningful Reduction in Mouth and Throat Soreness (MTS): Phase 3 Results. Session Type: Oral Session
Non-Myeloablative Matched Related Donor Transplantation
[689] Reduced-Intensity Conditioning Lowers Treatment-Related Mortality (TRM) of Allogeneic Stem Cell Transplantation (SCT) for CLL: A Retrospective Study on 448 Patients. Session Type: Oral Session
[690] Allogeneic Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning Regimen (RICT): Impact of Pretransplant and Posttransplant Factors on Outcome. A Study from La Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Session Type: Oral Session
Immunotherapy and Preclinical Studies
[3340] T- and B-Cell Response to the Anaplastic Lymphoma Kinase (ALK) Protein in Patients with ALK-Positive Anaplastic Large Cell Lymphoma (ALCL). Session Type: Poster Session 560-III
[3341] Single Agent Activity of FavId [Id-KLH vaccine] for Indolent NHL. Session Type: Poster Session 561-III
[3342] Immune Responses and Clinical Outcome of Patients with Advanced Non-Hodgkins Lymphoma after Immunization with a Novel Recombinant Idiotype Vaccine. Session Type: Poster Session 562-III
[3343] Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine Therapy in Patients with Relapsed or Previously Untreated Low-Grade Non-Hodgkin Lymphoma. Session Type: Poster Session 563-III
[3345] Early and Robust Immune Responses to Idiotype (Id) Vaccination Occur in Mantle Cell Lymphoma (MCL) and Indolent Lymphoma (IL) Patients Following Autologous Stem Cell Transplantation (ASCT). Session Type: Poster Session 565-III
[3347] Favid [Id-KLH vaccine] Following Rituximab for Patients with Indolent NHL. Session Type: Poster Session 567-III
[3350] Graft-Versus-Lymphoma Effect in Peripheral T-Cell Lymphomas (PTCL): Reduced-Intensity Conditioning Followed by Allogeneic Transplantation Gives a Better Outcome Than High-Dose Chemotherapy Followed by Autografting. Session Type: Poster Session 570-III
[3358] A Phase II Study of Bortezomib in Patients with Mantle Cell Lymphoma . Session Type: Poster Session 578-III
[3359] PS341 Inhibits Cell Proliferation, Induces Apoptosis of and Enhances the Biological Effects of Rituximab on Non-Hodgkins Lymphoma (NHL) Cell Lines and Lymphoma Xenografts. Session Type: Poster Session 579-III
[3360] Immunomodulatory Thalidomide Derivatives Have Activity Against Tumor Cells from Waldenstroms Macroglobulinemia. Session Type: Poster Session 580-III
[3362] Efficacy of the Proteasome Inhibitor PS-341 (Velcade) in Peripheral T Cell Lymphomas and HTLV-I Associated Adult T-Cell Leukemia/Lymphoma. Session Type: Poster Session 582-III
Experimental Transplantation: Engraftment
[3497] Interleukin-15 Enhances Immune Reconstitution after Allogeneic Bone Marrow Transplantation. Session Type: Poster Session 717-III
[3505] Factors Influencing Thymic Function after Stem Cell Transplantation. Session Type: Poster Session 725-III
Stem Cell Mobilization and Processing II
[3547] Kinetic of G-CSF and CD34+ Cell Mobilization after Once or Twice Daily Stimulation with Recombinant Human Granulocyte Stimulating Factor (Lenograstim) in Healthy Volunteers. An Intraindividual Cross-Over Study. Session Type: Poster Session 767-III
[3548] Addition of Rituximab to Mobilization and Preparative Regimens Successfully Purges CD20 NHL and Results in Durable Engraftment after Autologous PBSCT. Session Type: Poster Session 768-III
[3549] Peripheral Blood Stem Cell (PBSC) Mobilization with High-Dose vs. Low-Dose G-CSF: Analysis of a Case Control Series. Session Type: Poster Session 769-III
[3550] Autologous Stem Cell Collection and Measurement of Minimal Residual Disease in Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate. Session Type: Poster Session 770-III
[3552] Peripheral Blood Stem Cell (PBSC) from HIV-Positive Patients (pts) with Lymphoma Have Normal Proliferative Capacity and Allow Prompt and Sustained Hematopoietic Recovery after Myeloablative Treatment. Session Type: Poster Session 772-III
[3553] Hematopoietic Progenitor/Stem Cell Mobilization after Prior Autologous Blood and Marrow Transplant (BMT). Session Type: Poster Session 773-III
[3557] Intermediate Dose Etoposide + G-CSF Shows Higher PBPC Mobilization Efficacy and Shorter Hospitalization in Respect to Cyclophosphamide 4 gr/m2 + G-CSF . Session Type: Poster Session 777-III
[3565] Intermediate Dose Cyclophosphamide Followed by Sequential GM-CSF and G-CSF Produces Efficient and Predictable PBPC Mobilization for Autografting: A Single Center Study of One Hundred and Thirty-Five Patients. Session Type: Poster Session 785-III
[3569] Feasibility of Collecting Granulocyte Colony-Stimulating Factor (G-CSF)-Mobilized Peripheral Blood Stem Cells (PBSC) from Donors Aged over 50 Years. Session Type: Poster Session 789-III
[3572] The Impact of the Hyper-CVAD Chemotherapy Regimen on the Ability To Mobilize Peripheral Blood Stem Cells (PBSC) in Patients with Hematological Malignancies. Session Type: Poster Session 792-III
Cell Processing: Selection, Expansion, Purging, and Depletion
833] Transplantation with Ex Vivo Expanded Mobilized Blood CD34+ Cells Results in Reduction in Depth and Duration of Neutropenia and Thrombocytopenia, with Major Impact on Febrile Neutropenia, Platelet Transfusion and Hospital Admissions. Session Type: Oral Sess
[837] Rapid Engraftment and Conserved Graft-Versus-Leukemia Effect without Transplant-Related Mortality in Elderly Recipients of Allografts Selectively Depleted of Host-Reactive Lymphocytes. Session Type: Oral Session
[3583] A Unique New Cell Selection Technology: Applications for Purging Unwanted Cell Populations. Session Type: Poster Session 803-III
[3585] Ex Vivo Expanded Bone Marrow Combined with Sub-Therapeutic Dose of Peripheral Blood Progenitor Cells after High-Dose Chemotherapy in Poor Mobilizers. Session Type: Poster Session 805-III
[3586] Delayed B-Cell Recovery after In-Vivo Rituximab Purging vs. Delayed Myeloid Engraftment after Ex-Vivo CD34+ Cell Enrichment: Interim Analysis of a Randomized Phase II Trial of B-Lymphocyte Purging of Autologous PBPCs in NHL. Session Type: Poster Session 806-III
Transplantation Regimen Toxicities and Engraftment III
[841] Survival after Hematopoietic Cell Transplantation According to Ethnic Background. Session Type: Oral Session
[842] Outcomes of Graft Failure/Rejection Following Allogeneic Hematopoietic Cell Transplantation: 10-Year Experience at FHCRC. Session Type: Oral Session
[847] Factors Influencing Team Decisions for Hematopoetic Stem Cell Transplants. Session Type: Oral Session
[3605] Darbepoetin Alpha Is an Effective Therapy for Anemia Post Allogeneic Stem Cell Transplantation. Session Type: Poster Session 825-III
[3609] Donor Lymphocyte Infusion (DLI) 6 Months after In Vitro T-Cell Depleted Non-Myeloablative Stem Cell Transplantation Induces Rapid Conversion to Full Donor Chimerism in Patients with High Risk Malignancies. Session Type: Poster Session 829-III
[1700] Pilot Study of Recombinant Erythropoietin after Reduced Intensity Conditioning (RIC) for Allogeneic Stem Cell Transplantation (ASCT). Session Type: Poster Session 812-I
[1703] Full Donor Chimerism Is Required for Stable Engraftment and Durable Disease Control after Nonmyeloablative (NM) Allogeneic Blood or Marrow Transplants (BMT). Session Type: Poster Session 815-I
[1707] Amifostine Reduces High-Dose Melphalan Related Gastro-Intestinal Toxicity: Results from an Australasian Leukaemia and Lymphoma Group (ALLG) Randomised Trial. Session Type: Poster Session 819-I
Infections: Complications
[3616] Very Low Dose Aciclovir Prophylaxis Post Allogeneic Stem Cell Transplantation Prevents Varicella Zoster Infection without Development of Clinically Relevant Resistance. Session Type: Poster Session 836-III
[3617] Factors Influencing Measles Immunity after Allogeneic Stem Cell Transplantation. Session Type: Poster Session 837-III
[3618] FDG-PET Has a Significant Impact on the Diagnosis and Management of Infection in Patients with Hematological Cancer: A Study of 73 Infections in 67 Patients. Session Type: Poster Session 838-III
[3629] Evaluation of Late Occurring Invasive Pulmonary Aspergillosis (IPA) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) by High-Resolution Computed Tomography (HR-CT). Session Type: Poster Session 849-III
[3633] Steroids Prevent Engraftment Syndrome after Autologous Hematopoietic Stem Cell Transplantation without Increasing the Incidence of Infections. Session Type: Poster Session 853-III
Secondary Neoplasia and Late Complications After Transplantation
[3643] Poor Stem Cell Harvests Increase the Risk of Myelodysplastic Syndrome and/or Acute Myelogenous Leukemia (MDS/AML) Following Autologous Stem Cell Transplant (ASCT). Session Type: Poster Session 863-III
[3650] Competing Risks of Late Toxicity Post Autologus Stem Cell Transplantation (ASCT): Incidence and Characteristics in Aggressive Non Hodgkin Lymphoma Patients (NHL). Session Type: Poster Session 870-III
[3651] Decreased Bone Mineral Density after Autologous Stem Cell Transplantation. Session Type: Poster Session 871-III
Autologous Transplantation: Clinical Results
[3671] Significant Increase of Secondary Myelodysplasia and Acute Myeloid Leukemia after Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in Indolent Lymphoma Patients - Results of a Prospective Randomized Study for the GLSG. Session Type: Poster Session 891-III
[3673] Financial Costs and Time Commitments of the Primary Caregivers of Autologous Hematopoietic Stem Cell Transplant Patients. Session Type: Poster Session 893-III
[3674] Follow-Up of Autologous Stem Cell Transplantation (SCT) for Treatment of Waldenstroem`s Macroglobulinemia. Session Type: Poster Session 894-III
[3675] Infusion of Higher CD34+ Cell Doses in Stem Cell Products Is Associated with Inferior Progression-Free Survival (PFS) after Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma (NHL). Session Type: Poster Session 895-III
Graft-versus-Host Disease
[849] Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Related Peripheral Blood Stem Cell Transplantation: Low Transplant Related Morbidity and Excellent GVHD Control. Session Type: Oral Session
[850] Safety and Efficacy of Denileukin Diftitox in Patients with Steroid Refractory Graft-versus-Host Disease (GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) . Session Type: Oral Session
[853] Non-Myeloablative Stem Cell Transplantation (NST) Is Associated with Reduced Inflammatory Cytokine Storm and a Decreased Incidence of Acute Graft-Versus-Host Disease (AGVHD) Compared to Myeloablative Stem Cell Transplantation (MST). Session Type: Oral Session
[854] Phase I/II Trial on the Use of Etanercept (Enbrel) and Solumedrol as Primary Treatment for Acute Graft-Vs-Host Disease (aGVHD). Session Type: Oral Session
Autologous Transplantation: Non-Hodgkin's Lymphoma
[865] Value of Autologous Stem Cell Transplantation in First Line Therapy of Follicular Lymphoma with High Tumor Burden: Final Results of the Randomized GOELAMS 064 Trial. Session Type: Oral Session
[866] Prognostic Factors for Aggressive Lymphoma Patients Treated with Front-Line Autotransplantation after Complete Remission: A Cohort Study on 330 Patients. Session Type: Oral Session
[867] Comparison of Outcome of High Dose Chemotherapy (HDT) and Autologous Stem Cell Transplantation (ASCT) in Peripheral T Cell Lymphoma (PTCL) vs. Diffuse Large B Cell Lymphoma (B-DLCL). Session Type: Oral Session
[869] Rituximab and Peripheral Blood Stem Cell Transplantation Produces Durable Remissions in Patients with Low Grade and Mantle Cell Lymphoma. Session Type: Oral Session
[870] A New Preparative Regimen for Older Patients with Aggressive CD 20-Positive B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined with High-Dose BEAM Followed by Autologous Hematopoietic Cell Transplantation (AHCT): Targeted Intensification without Increased Transplant-Related Toxicity. Session Type: Oral Session
[871] Tandem Transplant for Follicular Lymphoma in Patients under 60 Years. Session Type: Oral Session
[872] Long Term Results of Radioimmunotherapy with Bexxar/BEAM and Autologous Stem Cell Transplantation (ASCT) for Chemotherapy Resistant Aggressive Non-Hodgkins Lymphoma (NHL). Session Type: Oral Session
Disordered Gene Expression in Hematologic Malignancy I
[1313] Prognostic Stratification in Follicular Lymphoma by Gene Expression Profiling to Guide the Choice of Treatment. Session Type: Poster Session 425-I
Clinicopathologic/Molecular Factors Impacting Prognosis I
[1417] Loss of MHC Class II Gene and Protein Expression in Diffuse Large B Cell Lymphoma Is Related to Decreased Tumor Immunosurveillance and Poor Patient Survival: A Follow-Up Study to the NIH Directors Challenge Leukemia and Lymphoma Molecular Profiling Project (LLMPP). Session Type: Poster Session 529-I
[1418] Analysis of Tumor-Specific T Cell Immune Response in Follicular Non-Hodgkins Lymphoma Patients Treated with Rituximab. Session Type: Poster Session 530-I
[1419] Prediction of Survival in Diffuse Large B-Cell Lymphoma (DLBCL) Based on the Expression of Six Genes. Session Type: Poster Session 531-I
[1427] 18 F-fluorodesoxyglucose Positron Emission Tomography in Aggressive Non-Hodgkins Lymphoma: An Early Prognostic Tool for Predicting Patient Outcome. Session Type: Poster Session 539-I
[1431] Follicular Lymphoma Grade 3 Is Not Equivalent to Follicular Large Cell Lymphoma: Comparison of the WHO and IWF Classification System. Session Type: Poster Session 543-I
[1432] Impact of FDG Positron Emission Tomography in Addition to Conventional Staging Procedures in Patients with Hodgkin's Lymphoma. Session Type: Poster Session 544-I
[1433] Expression of CD21 Antigen in Diffuse Large B-Cell Lymphoma and Prognostic Significance. Session Type: Poster Session 545-I
[1436] The Utility of Fine-Needle Aspiration (FNA) as a Diagnostic Technique in Lymphoma. Session Type: Poster Session 548-I
[1437] Increased Angiogenesis Predicts Favourable Outcome in Patients with Follicular Lymphoma Treated with the Combination of Chemotherapy and Interferon-Alpha2b. Session Type: Poster Session 549-I
[1443] Rituximab Is Associated with Late Onset Neutropenia (LON) when Administered with Doxorubicin-Based Chemotherapy for the Initial Treatment of Aggressive B-Cell Lymphomas. Session Type: Poster Session 555-I
Lymphoma: Treatment
[1446] Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. Session Type: Poster Session 558-I
[1447] Rituximab vs. Nothing after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Results of the First Interim Analysis of the Randomized LNH98-B3 GELA Study. Session Type: Poster Session 559-I
[1449] Primary Nasal Natural Killer Cell Lymphoma: Long-Term Treatment Outcome and Relationship with the International Prognostic Index. Session Type: Poster Session 561-I
[1450] Primary CNS Lymphoma Results of a Multicenter Phase II Study Including High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy. Session Type: Poster Session 562-I
[1452] A Brief Course of Chemo-Immunotherapy FND + Rituximab Is Effective To Induce a High Clinical and Molecular Response In Elderly Patients With Advanced Stage Follicular Lymphoma (FL) at Diagnosis. Session Type: Poster Session 564-I
[1453] Conventional Second-Line Salvage Chemotherapy Regimens Are Not Warranted in Patients with Malignant Lymphomas Who Have Progressive Disease in Response To First Line Salvage Chemotherapy Regimens. Session Type: Poster Session 565-I
[1454] Sphingosomal Vincristine Plus Rituximab for Treatment of Large B-Cell Lymphoma. Session Type: Poster Session 566-I
[1456] High Clinical and Molecular Response Rates with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) in Previously Untreated Patients with Advanced Stage Follicular Lymphoma (FL). Session Type: Poster Session 568-I
[1457] Results of Three Consecutive CHOP-Based Strategies in HIV-Related Diffuse Large B-Cell Lymphomas. Experience in 71 Patients. Session Type: Poster Session 569-I
[1462] Phase II Study of ProMACE-CytaBOM with Trimethoprim Sulfamethoxazole, Granulocyte Colony Stimulating Factor (G-CSF) and Antiretroviral Therapy in Patients with AIDS Related Non Hodgkins Lymphoma (AIDS-NHL), (S9320). Session Type: Poster Session 574-I
[1465] Chemotherapy Versus Chemo-Radiotherapy for High Grade Gastric Non Hodgkins Lymphomas: Preliminary Results of a Randomized Clinical Trials. Session Type: Poster Session 577-I
[1468] Bendamustine / Mitoxantrone / Rituximab (BMR): A New Effective Treatment for Refractory or Relapsed Indolent Lymphomas. Final Evaluation of a Pilot Study. Session Type: Poster Session 580-I
[1469] Pentostatin and Cyclophosphamide, Followed by Maintenance Therapy with Rituximab, for Previously Treated Patients with B-Cell Chronic Lymphocytic Leukemia and Waldenstrms Macroglobulinemia. Session Type: Poster Session 581-I
[1471] Randomized Comparison of Standard CHOP and Biweekly CHOP with Prophylactic Using G-CSF in Aggressive Non-Hodgkins Lymphoma . Session Type: Poster Session 583-I
[1473] Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma Results of Multicenter Phase II Study. Session Type: Poster Session 585-I
Radioimmunotherapy and Rituximab Combinations
[1474] Long-Term Results of a Randomized Trial Comparing Tositumomab and Iodine-131 Tositumomab (BEXXAR®) with Tositumomab Alone in Patients with Relapsed or Refractory Low-Grade (LG) or Transformed Low Grade (T-LG) Non-Hodgkin’s Lymphoma (NHL). Session Type: Poster Session 586-I - 6:00 pm - Hall DE
[1475] A Phase I Trial of Two-Sequential Doses of Zevalin™ Radioimmunotherapy for Relapsed Low-Grade B-Cell Non-Hodgkin's Lymphoma. Session Type: Poster Session 587-I - 6:00 pm - Hall DE
[1476] A Phase II Study of 90Yttrium-ibritumomab (Zevalin) for the Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL). Session Type: Poster Session 588-I - 6:00 pm - Hall DE
[1477] Initial Treatment of Mantle Cell Lymphoma with Sequential Radioimmunotherapy with Tositumoamb/Iodine I131 I-Tositumoamb followed by CHOP Chemotherapy Results in a High Complete Remission Rate. Session Type: Poster Session 589-I - 6:00 pm - Hall DE
[1478] Re-Treatment with Tositumomab and Iodine I 131 Tositumomab (the BEXXAR® Therapeutic Regimen) in Patients with Non-Hodgkin’s Lymphoma (NHL) with a Previous Response to the BEXXAR Therapeutic Regimen. Session Type: Poster Session 590-I - 6:00 pm - Hall DE
[1479] Outcome and Absorbed Dose Following 90-Yttrium-Epratuzumab in B-Cell Lymphoma, Using a Dose-Fractionation Schedule. Session Type: Poster Session 591-I - 6:00 pm - Hall DE
[1480] Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy (RIT) Induces Durable Remissions in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL): Analysis of Long-Term Responders. Session Type: Poster Session 592-I - 6:00 pm - Hall DE
[1481] Early Clinical Data for LymphoRad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. Session Type: Poster Session 593-I - 6:00 pm - Hall DE
[1482] Fractionated-Dose Radioimmunotherapy in Non-Hodgkin’s Lymphoma (NHL) Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody (Epratuzumab). Interim Results. . Session Type: Poster Session 594-I - 6:00 pm - Hall DE
[1483] Higher Doses of Rituxan® Alter Pharmacokinetics and Biodistribution of Zevalin® but May Increase Responses; a Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular/Transformed Non-Hodgkin’s Lymphoma. Session Type: Poster Session 595-I - 6:00 pm - Hall DE
[1484] Ibritumomab Tiuxetan (Zevalin™) Therapy Is Feasible and Safe for the Treatment of Patients with Advanced B-Cell Follicular NHL in First Remission: Interim Analysis for Safety of a Multicenter, Phase III Clinical Trial. Session Type: Poster Session 596-I - 6:00 pm - Hall DE
[1485] The BEXXAR® Therapeutic Regimen (Tositumomab and Iodine I 131 Tositumomab) Can be Safely Administered to Patients over the Age of 70. Session Type: Poster Session 597-I - 6:00 pm - Hall DE
[1487] Long Term Improvement of Clinical Outcome of Follicular Lymphoma Patients Achieving a Molecular Response after Sequential CHOP and Rituximab Treatment: Predictive Value of Real Time Quantitative PCR To Identify Responding Patients. Session Type: Poster Session 599-I - 6:00 pm - Hall DE
[1488] No Benefit from Rituximab in a Randomized Phase III Trial of CHOP with or without Rituximab for Patients with HIV-Associated Non-Hodgkin’s Lymphoma: Updated Data from AIDS Malignancies Consortium Study 010. Session Type: Poster Session 600-I - 6:00 pm - Hall DE
[1489] Anti-CD20 Monoclonal Antibody (Rituximab) in Gastric Extranodal Marginal Zone (MALT) Non-Hodgkin's Lymphoma (NHL) Patients: Clinical and Biological Results (Phase II Study). Session Type: Poster Session 601-I - 6:00 pm - Hall DE
[1490] Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma: Interim 24 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial). Session Type: Poster Session 602-I - 6:00 pm - Hall DE
[1491] Genasense (Bcl-2 Antisense) Plus Rituximab Is Active in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma. Session Type: Poster Session 603-I - 6:00 pm - Hall DE
[1492] Genasense™ Targeting Bcl-2 Protein Expression Enhances the Biological Anti-Tumor Activity of Rituximab Against Non-Hodgkin’s (NHL) Cell Lines and Lymphoma Xenografts. Session Type: Poster Session 604-I - 6:00 pm - Hall DE
[1493] Patients with Low-Grade NHL Treated with Rituximab + CHOP Experience Prolonged Clinical and Molecular Remission. Session Type: Poster Session 605-I - 6:00 pm - Hall DE
[1494] Phase II Study of Abbreviated Treatment (Short-Course) with EPOCH and Rituximab (EPOCH-R) in AIDS-Related Lymphoma (ARL): Preliminary Results on the Role of Rituximab in Treatment. Session Type: Poster Session 606-I - 6:00 pm - Hall DE
[1495] Antibody Dependent Cellular Cytotoxicity and Natural Killer Cell Activity in Patients with Recurrent Indolent Lymphoma Receiving Rituximab in Combination with GM-CSF. Session Type: Poster Session 607-I - 6:00 pm - Hall DE
[1496] Rituximab as First-Line and Maintenance Therapy for Indolent Non-Hodgkin's Lymphoma (NHL): Long-Term Follow-Up of a Minnie Pearl Cancer Research Network Phase II Trial. Session Type: Poster Session 608-I - 6:00 pm - Hall DE
[1499] A Phase II Study of Fludarabine Phosphate and Mitoxantrone Followed by Anti-CD20 Monoclonal Antibody in the Treatment of Patients with Newly Diagnosed, Advanced Low-Grade Non-Hodgkin’s Lymphoma (LGNHL): Interim Results. Session Type: Poster Session 611-I - 6:00 pm - Hall DE
Myeloablative Matched Related Donor Transplantation
[1732] Allogeneic Hematopoietic Stem Cell Transplantation (SCT) in Patients 50 Years of Age and Older: A Matched Control Study. Session Type: Poster Session 844-I - 6:00 pm - Hall DE
[1733] Total Bone Marrow CD34+ Cells and the Most Immature Subpopulations in the Late Postransplant Period Are Lower in Allo-SCT Patients Than They Are in Those of Their Respective Donors. Session Type: Poster Session 845-I - 6:00 pm - Hall DE
[1734] Outcomes of 100 Adult Matched Sibling Stem Cell Transplant (SCT) Recipients Given Pretransplant Low-Dose Antithymocyte Globulin (ATG) and Followed for at Least One Year. Session Type: Poster Session 846-I - 6:00 pm - Hall DE
[1735] Impact of Low CD34+ Cell Dose on Clinical Outcomes Following HLA-Identical Sibling Mobilized Peripheral Blood Progenitor Cell Transplantation. Session Type: Poster Session 847-I - 6:00 pm - Hall DE
[1736] Results of Allogeneic Transplantation Using Fully Myeloablative Preparation in Patients Who Are Candidates for Reduced Intensity Regimens. Session Type: Poster Session 848-I - 6:00 pm - Hall DE
[1737] Is Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Potentially Curative in a Group of Refractory Cutaneous T-Cell Lymphomas (CTCLs)? Durable Clinical, Cytogenetic and Molecular Remissions after AHSCT for Refractory Sezary Syndrome and Mycosis Fungoides. Session Type: Poster Session 849-I - 6:00 pm - Hall DE
Allogeneic Mismatched or Unrelated Donor Transplantation: Umbilical Cord Blood and Reduced Intensity Transplants
[1746] Comparison of Outcomes of Unrelated Bone Marrow and Umbilical Cord Blood Transplants with Reduced-Intensity Conditioning in Adults with Hematological Diseases: Results of a Matched-Pair Analysis. Session Type: Poster Session 858-I - 6:00 pm - Hall DE
[1747] Outcomes of 138 Adult and Pediatric Patients Undergoing Cord Blood Transplantation from Large Cord Blood Bank. Session Type: Poster Session 859-I - 6:00 pm - Hall DE
[1748] Unrelated Cord Blood Transplantation in Adult Patients with Hematological Malignancy Is a Safe and Useful Therapeutic Modality. Session Type: Poster Session 860-I - 6:00 pm - Hall DE
[1749] Rapid Engraftment and Achievement of Complete Donor Chimerism in Adult Patients with Hematological Disease Following Unrelated Umbilical Cord Blood Transplantation Using a Reduced-Intensity Conditioning (RI-UCBT). Session Type: Poster Session 861-I - 6:00 pm - Hall DE
[1750] Prognostic Factors for Adult Cord Blood Transplantation: Follow-Up of 62 Adult Patients with Units Shipped from a Single Cord Blood Bank, Tokyo Cord Blood Bank. Session Type: Poster Session 862-I - 6:00 pm - Hall DE
Allogeneic Mismatched or Unrelated Donor Transplantation: Clinical Outcomes
[1777] Impact of Transplant CD34+ Cell Dose on Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor. Session Type: Poster Session 889-I
[1780] Hematopoietic Stem Cell Transplantation: In Patients above 40 Years Young HLA-Matched Unrelated Donors Should Be Preferred to HLA-Identical Sibling Donors. Session Type: Poster Session 892-I
1783] Development of Grade II to IV Acute GVHD Is Associated with Lower Incidence of Disease Progression After Unrelated Bone Marrow Transplantation for Non-Hodgkins Lymphoma. A Study from the Japan Marrow Donor Program (JMDP). Session Type: Poster Session 895-I
[1785] Lack of Severe Acute Graft-Versus-Host Disease Following Transplantation of Purified CD34+CD133+ Cells with T-Cell Add-Back from Unrelated Donors. Session Type: Poster Session 897-I
[1789] Reduced-Intensity Regimen for Unrelated Donor Transplantation (UDT) as Salvage Therapy for Prior Recipients of Autologous Stem Cell Transplantation. Session Type: Poster Session 901-I
Uncategorized Publication only abstracts
[3737] A Randomized Trial Evaluating the Pharmacologic and Hematologic Effects of the Timing of Darbepoetin Alfa and Chemotherapy Administration. Session Type: Publication Only
[3763] Successful Use of Rituximab with Prednisone,Cyclosporine, Immunoglobulin and Erythropoietin in a Jehovah's Witness Patient with Pure Red Cell Aplasia Associated with CLL. Session Type: Publication Only
[3775] Rapid Response with Epoetin Beta (NeoRecormon®) Once Weekly or Three Times Weekly in Anemic Patients with Lymphoid Malignancies. Session Type: Publication Only
[3776] Costs of Once Weekly Treatment with Epoetin in Anemic Patients with Hematological Malignancies . Session Type: Publication Only
[3783] Results of a Randomized Study of Every Three-Week Dosing (Q3W) of Darbepoetin Alfa for Chemotherapy-Induced Anemia (CIA). Session Type: Publication Only
[3887] The Importance of Optimal Filgrastim Dosing To Support Intensive Chemotherapy of Cancer. Session Type: Publication Only
[3888] GM-CSF-Based Vaccines: Is Too Much of a Good Thing Bad? Session Type: Publication Only
[3897] Efficacy of CHOP Regimen as First Line Therapy in Posttransplantation Lymphoproliferative Disorders ( PTLD). A Retrospective Study on 25 Cases. Session Type: Publication Only
[4013] Vascular Endothelial Growth Factor (VEGF) Induces Enhanced Fibrinolytic Activity of Endothelial Cells Via Rapid Pro-Urokinase (pro-uPA) Activation. Session Type: Publication Only
[4014] Statin beyond Lipid Lowering: Lovastatin and Angiogenesis-Mediated Processes. Session Type: Publication Only
[4178] Isotype Distribution in Anti-Cardiolipin (aCL) and Anti-Phosphatidylserine (aPS)- Positive Clinical Samples. Session Type: Publication Only
[4245] Blood Transfusion Requirements and Febrile Complications after Autologous Stem Cell Transplantation. Session Type: Publication Only
[4263] In Vitro Response to Tpo of Purified CD34+ Cells and Platelet Recovery Time in Patients with Malignant Lymphoma after AutoPBSCT. Session Type: Publication Only
[4312] Autologous Peripheral Stem Cell Transplantation in Patients with Congestive Heart Failure Due to Ischemic Heart Disease. Session Type: Publication Only
[4318] Study of Hematopoietic Progenitor Cells in Patients with Myocardial Infarction. Session Type: Publication Only
[4319] Reduction of Radiation-Induced Damage to Salivary Glands by Bone Marrow Derived Stem Cells after G-CSF Mobilization. Session Type: Publication Only
[4364] “Cross Lineage” Effects of darbepoetin alfa in Normal Mice: A Comparison with Recombinant Human Erythropoietin, darbepoetin alfa and Pegylated-darbepoetin alfa. Session Type: Publication Only
[4390] Optimizing the Use of Colony Stimulating Factors in Reducing the Risk of Febrile Neutropenia. Session Type: Publication Only
[4393] Pegfilgrastim vs. Filgrastim in Reducing Risk of Febrile Neutropenia. Session Type: Publication Only
[4516] Genasense TM (Bcl-2 Antisense) Enhances the Response to Imatinib by BCR-ABL-Transformed Cells. Session Type: Publication
Only
[4537] G3139-Genasense® Induces Apoptosis of Chronic Lymphocytic Leukemia Cells Via a Mechanism Dependent upon the Presence of Thymidine Nucleotides and Phosphorothioate Backbone and Not Antisense Bcl-2 Sequence. Session Type: Publication Only
[4546] Establishment of Rituximab Resistant Human Burkitt's Lymphoma Cells In Vitro and Ellucidation of This Mechanism. Session Type: Publication Only
[4676] Biologic Effects of Curcumin on Apoptosis in Acute and Chronic Myelogenous Leukemia. Session Type: Publication Only
[4735] Phase I Study of ABT-751, a Novel Tubulin-Binding Agent, in Patients with Refractory Hematological Malignancies. Session Type: Publication Only
[4777] Prognostic Significance of Extranodal Involvement in B-Cell Non-Hodgkin´s Lymphoma (NHL). Session Type: Publication Only
[4778] Morphologic, Flow Cytometric and Cytogenetic Evaluation of Bone Marrow Involvement in B-Cell Lymphoma. Session Type: Publication Only
[4780] Analysis of 37 Pathological and Clinical Data of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT). Session Type: Publication Only
[4782] Association between Simian Virus 40 DNA and Malignant Lymphoma. Session Type: Publication Only
[4787] Central Nervous System Involvement in Indolent Lymphomas. Session Type: Publication Only
[4791] Non-Hodgkin’s Lymphoma in India: Dissimilarities from the West. Session Type: Publication Only
[4797] Prospective Randomized Study Comparing the Third Generation VACOP-B Regimens Versus 6 Week VACOP-B Plus High-Dose Sequential Followed by Autologous Bone Marrow Transplantation in Unselected High-Risk IPI Non Hodgkin’s Lymphoma. A GEMOH Report. Session Type: Publication Only
[4805] Significant Differences of the Standard Uptake Values (SUV) from PET Scan between Indolent and Aggressive Lymphomas. Session Type: Publication Only
[4814] Development and Validation of a Prognostic Model For Waldenstrom's Macroglobulinemia(MW). Session Type: Publication Only
[4822] Primary Non-Hodgkin’s Lymphomas of the Lung. Session Type: Publication Only
[4825] Positron Emission Tomography Versus Gallium scintigraphy as a Prognostic Test during Chemotherapy for Non Hodgkin's Lymphoma (NHL). Session Type: Publication Only
[4826] The Role of Flow Cytometry on Lymph Node Tissue as a Diagnostic Tool in Lymphoproliferative Disease - Comparative Assessment with Conventional and Molecular Studies. Session Type: Publication Only
[4833] Family Clustering of Hematological Cancer as a Risk Factor for Lymphoma. Session Type: Publication Only
[4844] Lack of Clinical Risk Factors in Patients Diagnosed with Primary Mediastinal Large-B-Cell Lymphoma (PMLBCL). Session Type: Publication Only
[4845] Prognostic Factors in Follicular Lymphoma: The Importance of Beta-2 Microglobulin. Session Type: Publication Only
[4846] Magnetic Ressonance Imaging (MRI) in Lymphoproliferative Disorders as Bone Marrow Involvement Marker. Session Type: Publication Only
[4859] Rituximab and CHOP Every 14-Days (R-CHOP 14) in Younger Patients with Advanced Diffuse Large-B-Cell Non-Hodgkin’s Lymphoma (DLBCL) – An Update of Efficacy and Safety. Session Type: Publication Only
[4860] Oral Fludarabine/Cyclophosphamide Combination in Pretreated Indolent Non-Hodgkin's Lymphomas. Session Type: Publication Only
[4861] Gemcitabine as Single Agent in the Treatment of Relapsed and Refractory Hodgkin’s and Non-Hodgkin Lymphoma. Session Type: Publication Only
[4862] High Dose Methotrexate Based Chemotherapy in Renal Transplant Recipients with Primary Central Nervous System Lymphoma. Session Type: Publication Only
[4868] Preliminary Results of a Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Rituxan, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Aggressive B-Cell Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4870] Dose-Intense Cyclophosphamide and Etoposide for Patients with Refractory or High Risk Non-Hogdkin's Lymphoma. Session Type: Publication Only
[4873] Adapted CHOP Chemotherapy Plus Rituximab in Patients over 80 Years with Non-Hodgkin's Lymphoma. Session Type: Publication Only
[4875] A Phase II Trial of Rituximab Plus ESHAP as Salvage Chemotherapy in Relapsed/Refractory Aggressive Histology Non-Hodgkin's Lymphoma. Session Type: Publication Only
[4876] Treatment of Waldenstrom Macroglobulinemia with the Combination of Fludarabine and Cyclophosphamide: Results in 21 Patients (pts). Session Type: Publication Only
[4877] Paclitaxel and Topotecan in Combination with Rituximab as Effective Salvage Regimen in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4878] Safety and Efficacy of Pegylated Liposomal Doxorubicin for the Treatment of Advanced Cutaneous T-Cell Lymphoma. Session Type: Publication Only
[4883] Phase II Pilot Study of Modified Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Session Type: Publication Only
[4886] A Prospective Multicenter Study of the BMPD Regimen with or without Radiotherapy for Primary CNS Lymphoma. Session Type: Publication Only
[4888] Fludarabine(F), Cytoxan(C) and GM-CSF Combination in the Treatment of Patients with Relapsed Chronic Lymphocytic Leukemia(CLL) and Low Grade Non-Hodgkin's Lymphoma (LGNHL). Session Type: Publication Only
[4889] Preliminary Results of a Nordic Phase II Study on Dose-Intensive Induction and High-Dose Therapy (HDT) with Autologous Stem Cell Rescue (ASCR) as Primary Treatment for Peripheral T-Cell Lymphomas (PTCL). Session Type: Publication Only
[4890] Phase II Study of High-Dose Methotrexate, Thiotepa, Vincristine and Dexamethasone for Primary CNS Lymphoma. Session Type: Publication Only
[4893] A Phase I Study of Dose Escalated Cytarabine in Combination with a Modified ESHAP-Like Regimen, Paclitaxel, and Vinorelbine (VTEPA) for the Treatment of Relapsed/Refractory Lymphoma. Session Type: Publication Only
[4895] Fludarabine-Induced Toxicity in Treatment of Chronic Lymphoproliferative Disorders. Session Type: Publication Only
[4897] A Pilot Study of Rituximab and High-Dose Bi-Weekly THP-COP with G-CSF Support (R-HDBWTCOP(G)) for Low-Grade Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4899] Long-Term Results with Rituximab in Previously -Treated Patients with Low-Grade Non-Hodgkin's Lymphoma. Session Type: Publication Only
[4901] Efficacy Controls and Long-Term Follow-Up of Patients (Pts) Treated with FC Plus Rituximab for Relapsed Follicular NHL. Session Type: Publication Only
[4902] Interim Report of an Historically Controlled Trial of Rituximab after Autologous Stem Cell Transplantation for Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4903] High-Dose Chemoadiotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Mediastinal Large B-Cell Lymphoma. Session Type: Publication Only
[4912] Rituximab Followed by Cladribine in the Treatment of Heavily Pretreated Patients with Indolent Lymphoid Malignancies. Session Type: Publication Only
[4915] Maintenance Therapy Using the Anti-CD20 Antibody Rituximab in Patients with B-Cell Non-Hodgkin Lymphoma . Session Type: Publication Only
[4919] Rituximab as a Single Agent in Splenic Marginal Zone Lymphoma Can Obviate the Need for Splenectomy. Session Type: Publication Only
[4920] An Open Label, Pilot Study of Pentostatin, Mitoxantrone, and Rituximab, in Previously Untreated, Stage III or IV, Low-Grade Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4921] Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX): A Promising Salvage Regimen for Refractory/Relapsed B-Cell Lymphoma. A Pilot Study. Session Type: Publication Only
[4924] Continuous Complete Remission (CR) Following Reduced-Intensity Stem Cell Transplantation (RIST) Using Fludarabine and Busulfan with or without Total Body Irradiation in Patients with Refractory Peripheral T-Cell Lymphomas (PTCL), Unspecified. Session Type: Publication Only
[4925] Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma: Updated Results of a Multicenter Phase II Trial. Session Type: Publication Only
[4926] Re-Treatment with Rituximab: A Retrospective Analysis of Patients Treated in One Center. Session Type: Publication Only
[4927] A Prospective Analysis of B-Cell Reconstitution after Autologous Peripheral Blood Stem Cell Transplantation Using Grafts Purged In Vivo with Rituximab in Patients with Non-Hodgkin's Lymphoma. Session Type: Publication Only
[4928] An Open-Label, Randomised, Parallel, Phase II Study of CHOP Chemotherapy and Rituximab Administered Every 14 Days, with Pegfilgrastim or Filgrastim Support, for the Treatment of Subjects with Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4933] Follow-Up during Four Years after Anti CD20(Rituximab) Trial in Relapsed Follicular Lymphoma. Session Type: Publication Only
[4935] Analysis of a Phase II Study of Denileukin Diftitox (ONTAK®) for B and T-Cell Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[4936] Rituximab Maintenance Therapy Achieves a Long Term Remission in a Patient with Aggressive Lymphoma Who Relapsed after High Dose Chemotherapy. Session Type: Publication Only
[4940] Combination Chemotherapy of Rituximab, Fludarabine, Mitoxantrone and Dexamethasone for Refractory or Bulky Indolent B-Cell Lymphoma. Session Type: Publication Only
[4941] CNOP vs. CNOP-Rituximab vs. Rituximab Alone as First-Line Therapy for Indolent Non-Hodgkin Lymphoma (INHL): Preliminary Results. Session Type: Publication Only
[4949] Earlier Treatment with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Is Associated with Higher Response Rates and Longer Durations of Response in Patients with Previously Treated B-Cell Non-Hodgkin’s Lymphoma (NHL): Results with Second-Line Therapy. Session Type: Publication Only
[4950] ESHAP Combined with Rituximab and GMCSF Is Highly Active in Relapsed/Refractory Aggressive Lymphoma. Session Type: Publication Only
[4951] Phase I Results from a Multicenter Trial of Galiximab (Anti-CD80 Antibody, IDEC-114) in Combination with Rituximab for the Treatment of Follicular Lymphoma. Session Type: Publication Only
[4952] Initial Experience with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®): A Model for Successful Implementation of Radioimmunotherapy (RIT) in the Community Setting. Session Type: Publication Only
[4953] Vaccine Therapy of Follicular Lymphoma in First Remission: Long-Term Follow-Up of Phase II Results and High Rate of Chemotherapy-Induced Complete Remissions in a Controlled, Randomized Phase III Trial. Session Type: Publication Only
[5312] Hematopoietic Stem Cell Dose Correlates with the Speed of Immune Reconstitution after Stem Cell Transplantation. Session Type: Publication Only
[5349] UVA1-Phototherapy for Treatment of Acute Graft-Versus-Host Disease Confined to the Skin: A Pilot Experience. Session Type: Publication Only
[5378] Mobilization of Autologous Perpheral Blood Stem Cells by Combined Chemotherapy and rhG-CSF. Session Type: Publication Only
[5379] Collection of Hematopoetic Stem Cell in Allogeneic Female Donors during Menstrual Bleeding. Session Type: Publication Only
[5385] Comparison of Stem Cell Collections Using Two Different Cell Separators – Cobe Spectra and Baxter CS3000 in 514 Leukaphereses Procedures. Session Type: Publication Only
[5386] Bone Marrow CD34+ Cell Count Is Predictive of Successful Mobilization of Peripheral Hematopoietic Stem Cells. Session Type: Publication Only
[5387] Ancestim (Stem Cell Factor, SCF) in Combination with Filgrastim Can Mobilize Sufficient Peripheral Blood Progenitor Cells (PBPC) to Support High-Dose Salvage Chemotherapy and Late Intensification in Relapsing and Refractory Aggressive Non-Hodgkin's Lymphoma. A GELA Study. Session Type: Publication Only
[5391] Peripheral Blood Stem Cell Mobilisation on Patients with Autoimmune Diseases. Session Type: Publication Only
[5411] Bloodless Transplant: Autologous Stem Cell Transplant Can Be Performed Safely without the Use of Blood Product Support. Session Type: Publication Only
[5432] Decreasing Chronic Graft-Versus-Host Disease by Adding Median Dose of Rabbit Anti-Human Lymphocyte Globulin in Conditioning Regime. Session Type: Publication Only
[5479] Filgrastim (GCSF) Is Beneficial after Autologous Peripheral Blood Stem Cell Transplant (aPBSCT) with High CD34+ Cell Content. Session Type: Publication Only
[5480] Comparison of Lymphoid and Myeloid Engraftment Rates in Patients Receiving Fludarabine/TBI or Fludarabine/Cyclophosphamide for Non-Myeloablative Allogeneic Transplantation. Session Type: Publication Only
[5481] Effect on Platelet and Neutrophil Recovery of Administration of Filgrastim Post Transplant in Autologous Transplant Recipients. Session Type: Publication Only
[5524] Pentostatin and Cyclosporine for Prevention of Acute Graft-Versus-Host Disease after Allogeneic Peripheral Blood Progenitor Cell Transplantation. Session Type: Publication Only
[5526] In Vivo T-Cell Depletion with Low-Dose Alemtuzumab in Nonmyeloablative Allogeneic Transplants Is Associated with a Relatively Rapid Immunereconstitution and Reduced Incidence of Graft-Versus-Host Disease. Session Type: Publication Only
[5569] Outcome after Relapse Following Reduced-Intensity Stem-Cell Transplantation (RIST) from a Matched Related Donor for Hematologic Malignancy. Session Type: Publication Only
[5571] Second Hematopoietic Stem Cell Transplantation Using a Nonmyeloablative Approach: Low Toxicity Using a Fludarabine and Intravenous Busulfan Regimen. Session Type: Publication Only
[5596] Nonmyeloablative Allografting for Advanced Lymphoma: A Higher Than Expected Remission Rate and Rate Disease Control. Session Type: Publication Only
[5607] Sequential and Quantitative Analysis of Chimerism after Nonmyeloablative Stem Cell Transplantation: Results of a Single Center Study. Session Type: Publication Only
[5611] Reduced-Intensity Hematopoietic Stem Cell Transplants (RIST) Induces High Complete Remission with Tolerable Toxicity in Advanced Mantle Cell Lymphoma. Session Type: Publication Only
[5615] Allogeneic Hematopoietic Cell Transplantation for Refractory Waldenström's Macroglobulinemia - Replacing High-Dose Cytotoxic Therapy with Graft-versus-Tumor Effects. Session Type: Publication Only
[5651] Rituximab In Vivo Purging Combined with Auto Peripheral Blood Stem Cell Transplantation (APBST) and High-Dose Chemotherapy in Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[5658] Efficacy of Autologus Stem Cell Transplantation in Mantle Cell Lymphoma- a Single Institution Experience. Session Type: Publication Only
[5659] The Role of Salvage Therapy Post Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphoma. Session Type: Publication Only
[5661] The Clinical Outcome of Mantle Cell Lymphoma: Experience of the ‘STAR’ (Stem Cell Transplantation Program in the Antwerp Region) Group. Session Type: Publication Only
[5685] Surveillance of Serum Immunoglobulins after High-Dose Therapy/ASCT Plus Post-Transplant Consolidative Rituximab for Relapsed Follicular and New-Diagnosis Mantle Cell Lymphoma. Session Type: Publication Only
[5686] Does the Intensity of the Induction Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) Affect Long-Term Outcome for Patients with Newly Diagnosed Mantle Cell Lymphoma (MCL)? Session Type: Publication Only
[5690] High Dose Chemotherapy Followed by Autologous Peripheral Stem Cell Transplantation(HD-PSCT) for Poor Prognosis, Primary Resistant or Relapsed Aggressive Lymphoma- a Single Institute Experience. Session Type: Publication Only
[5692] High Dose Therapy/ASCT Consolidated by Rituximab and or Interferon Immunotherapy for Relapsed Follicular Lymphoma Achieves Durable Molecular Remissions and Improved Progression Free Survival. Session Type: Publication Only
[5715] Dendritic Cell Vaccines: Viral Versus Protein Transduction. Session Type: Publication Only
[5754] Rituximab for Indolent Lymphoma: An Analysis of Outcomes in a Large Population-Wide Study. Session Type: Publication Only
[5768] Evaluation of Dosing and Clinical Response to Darbepoetin Alfa (DA) and Epoetin Alfa (EPO) in Patients Treated for Chemotherapy-Induced Anemia in Hospital Oncology Outpatient Clinics. Session Type: Publication Only
[5772] Better Early and Overall Hematologic Outcomes and Lower Drug Cost with Epoetin Alfa (EPO) Compared with Darbepoetin Alfa (DARB). Session Type: Publication Only
[5778] Weekly Epoetin alfa (QW) Provides Similar Hematologic Outcomes to Front-Loading (FL) Darbepoetin alfa Regimens and Better Outcomes Compared to Darbepoetin alfa (Q2W) in Patients with Chemotherapy-Related Anemia. Session Type: Publication Only
![[4014] Statin beyond Lipid Lowering: Lovastatin and Angiogenesis-Mediated Processes. Session Type: Publication Only](http://www.marathonmultimedia.com/graphics/alphabet/apos.jpg){kind=link}